Baird analyst Joel Beatty upgraded Arcturus Therapeutics (NASDAQ: ARCT) from Underperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE